Faron Pharmaceuticals Oy (FARN) News Today GBX 198.76 +6.26 (+3.25%) As of 05/2/2025 11:39 AM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsHeadlinesBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Faron Announces Acceptance of Bexmarilimab Phase II Data for Oral Presentation at ASCO 2025April 24, 2025 | finance.yahoo.comFaron Pharmaceuticals Oy (LON:FARN) Stock Price Down 14% - Time to Sell?Faron Pharmaceuticals Oy (LON:FARN) Trading Down 14% - Should You Sell?April 18, 2025 | marketbeat.comFaron Pharmaceuticals Oy (LON:FARN) Hits New 1-Year High - Here's What HappenedFaron Pharmaceuticals Oy (LON:FARN) Sets New 12-Month High - Still a Buy?April 16, 2025 | marketbeat.comInside Information: Faron Announces Positive Phase II Results in Higher-risk Myelodysplastic SyndromeApril 15, 2025 | finance.yahoo.comFaron Pharmaceuticals Oy (LON:FARN) Stock Price Passes Above Fifty Day Moving Average - Should You Sell?Faron Pharmaceuticals Oy (LON:FARN) Share Price Crosses Above 50-Day Moving Average - What's Next?March 30, 2025 | marketbeat.comFaron Pharmaceuticals Oy (LON:FARN) Shares Cross Above Fifty Day Moving Average - Should You Sell?Faron Pharmaceuticals Oy (LON:FARN) Stock Passes Above Fifty Day Moving Average - Here's WhyMarch 21, 2025 | marketbeat.comShareholders’ Nomination Board updates its Recommendation on the Number of Board Members to be Elected and the Persons Proposed to be ElectedMarch 20, 2025 | finance.yahoo.comFaron Pharmaceuticals Oy (LON:FARN) Shares Pass Below 50 Day Moving Average - Here's WhyFaron Pharmaceuticals Oy (LON:FARN) Stock Passes Below 50 Day Moving Average - Time to Sell?March 13, 2025 | marketbeat.comFaron Pharmaceuticals Oy (LON:FARN) Stock Price Crosses Above 50 Day Moving Average - Time to Sell?Faron Pharmaceuticals Oy (LON:FARN) Shares Pass Above 50 Day Moving Average - What's Next?March 5, 2025 | marketbeat.comFaron Pharmaceuticals Oy: Inside Information: FDA Grants Orphan Drug Designation for Bexmarilimab in MDSMarch 3, 2025 | finanznachrichten.deFaron Pharmaceuticals Oy (LON:FARN) Shares Cross Below 50 Day Moving Average - Time to Sell?Faron Pharmaceuticals Oy (LON:FARN) Stock Crosses Below Fifty Day Moving Average - What's Next?February 25, 2025 | marketbeat.comFaron Pharmaceuticals Oy (LON:FARN) Shares Cross Below 200 Day Moving Average - Here's What HappenedFaron Pharmaceuticals Oy (LON:FARN) Stock Passes Below Two Hundred Day Moving Average - Here's What HappenedFebruary 15, 2025 | marketbeat.comFaron Pharmaceuticals Oy (LON:FARN) Stock Price Crosses Below 200-Day Moving Average - Should You Sell?Faron Pharmaceuticals Oy (LON:FARN) Shares Cross Below Two Hundred Day Moving Average - What's Next?February 15, 2025 | marketbeat.comFaron Pharmaceuticals Regulatory NewsFebruary 9, 2025 | lse.co.ukFaron Pharmaceuticals Oy (LON:FARN) Stock Crosses Below Fifty Day Moving Average - What's Next?Faron Pharmaceuticals Oy (LON:FARN) Share Price Crosses Below 50 Day Moving Average - Time to Sell?February 7, 2025 | marketbeat.comFaron Pharmaceuticals seeks EUR 10 million in private placementFebruary 5, 2025 | msn.comFaron completes enrollment for BEXMAB Phase II MDS studyJanuary 31, 2025 | msn.comFaron Pharmaceuticals Oy (LON:FARN) Share Price Passes Below 50 Day Moving Average - Here's WhyFaron Pharmaceuticals Oy (LON:FARN) Shares Cross Below 50-Day Moving Average - Should You Sell?December 27, 2024 | marketbeat.comFaron Pharmaceuticals Reports Promising BEXMAB Trial ResultsDecember 11, 2024 | markets.businessinsider.comFaron Pharma CEO talks about MHRA fast-track and phase III plans - ICYMIDecember 7, 2024 | uk.investing.comFaron Pharmaceuticals Oy (LON:FARN) Shares Up 1.3% - Still a Buy?Faron Pharmaceuticals Oy (LON:FARN) Trading Up 1.3% - Should You Buy?December 5, 2024 | marketbeat.comFaron Pharma secures UK innovation passport for blood cancer immunotherapyDecember 4, 2024 | msn.comFaron Pharmaceuticals Share Chat (FARN)December 2, 2024 | lse.co.ukFaron Pharmaceuticals Oy (LON:FARN) Stock Price Crosses Below 50-Day Moving Average - Time to Sell?Faron Pharmaceuticals Oy (LON:FARN) Stock Price Passes Below Fifty Day Moving Average - What's Next?November 13, 2024 | marketbeat.comFaron Pharmaceuticals Expands Pipeline with New PatentNovember 11, 2024 | msn.comFaron Pharmaceuticals Oy (LON:FARN) Share Price Crosses Above 50 Day Moving Average of $182.05Faron Pharmaceuticals Oy (LON:FARN) Shares Cross Above Fifty Day Moving Average of $182.05September 21, 2024 | marketbeat.comFaron Pharmaceuticals Oy (LON:FARN) Shares Down 8.8% Faron Pharmaceuticals Oy (LON:FARN) Shares Down 8.8%August 28, 2024 | marketbeat.comFaron Pharmaceuticals Oy (LON:FARN) Stock Price Up 27.3%Faron Pharmaceuticals Oy (LON:FARN) Trading Up 27.3%August 27, 2024 | marketbeat.comFaron Pharmaceuticals Share ChatJuly 31, 2024 | lse.co.ukFaron Pharmaceuticals Oy Appoints Juho Jalkanen as CEOApril 30, 2024 | marketwatch.comFaron Pharmaceuticals Oy: Faron Confirms Plans for the Coming Months Under New LeadershipApril 16, 2024 | finanznachrichten.deFaron Confirms Plans for the Coming Months Under New LeadershipApril 16, 2024 | finance.yahoo.comInside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AMLMarch 18, 2024 | finance.yahoo.comFaron Pharmaceuticals reports promising phase 1 results from BEXMAB studyMarch 18, 2024 | finance.yahoo.comFaron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of BexmarilimabMarch 14, 2024 | finance.yahoo.comFaron’s Financial Statement Release January 1 to December 31, 2023March 13, 2024 | finance.yahoo.comFaron Pharma secures €3.2 million convertible loanMarch 4, 2024 | uk.investing.comNasdaq Helsinki Ltd: THE SHARES OF FARON PHARMACEUTICALS LTD. GIVEN OBSERVATION STATUSFebruary 19, 2024 | finanznachrichten.deFaron Pharmaceuticals Oy (FARN)February 1, 2024 | uk.investing.comFaron Pharmaceuticals Oy: Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS PopulationJanuary 25, 2024 | finanznachrichten.deDetailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS PopulationJanuary 25, 2024 | finance.yahoo.comFaron Pharmaceuticals Oy (FARN.L)January 23, 2024 | finance.yahoo.comFaron Pharmaceuticals Oy: Inside information: Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB TrialJanuary 11, 2024 | finanznachrichten.deFaron Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceJanuary 3, 2024 | finance.yahoo.comFaron Pharmaceuticals presents "very positive" Phase 1 data at ASH ConferenceDecember 11, 2023 | finance.yahoo.comFaron Pharmaceuticals hails positive results of cancer drug trialDecember 11, 2023 | lse.co.ukInside information: Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial at the 65th American Society of Hematology (ASH) Annual MeetingDecember 11, 2023 | finance.yahoo.comFaron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports MedicineDecember 7, 2023 | finance.yahoo.comFaron Pharmaceuticals Oy FARNNovember 24, 2023 | morningstar.comFaron Pharmaceuticals initiates second phase of BEXMAB studyNovember 6, 2023 | finance.yahoo.com Get Faron Pharmaceuticals Oy News Delivered to You Automatically Sign up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter. Email Address FARN Media Mentions By Week FARN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FARN News Sentiment▼0.000.73▲Average Medical News Sentiment FARN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FARN Articles This Week▼00▲FARN Articles Average Week Get Faron Pharmaceuticals Oy News Delivered to You Automatically Sign up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Genus News PureTech Health News Oxford Biomedica News 4basebio News Bioventix News Avacta Group News hVIVO News Scancell News Ondine Biomedical News SkinBioTherapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:FARN) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Faron Pharmaceuticals Oy Please log in to your account or sign up in order to add this asset to your watchlist. Share Faron Pharmaceuticals Oy With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.